atitis B vaccination in haemodialysis patients. J Viral Hepat
healthy individual hepatitis B vaccine non-responders [14, 15] . 9 . Dumann H, Meuer SC, Renschin G, Kö hler H. Influence of Groß et al. reported in their pilot study the success of thymopectin on antibody response and monocyte and T cell adjuvant interferon-a therapy only in the group of lowfunction in hemodialysis patients who fail to respond to hepatitis responder patients in which the interferon-a was added to B vaccination. Nephron 1990; 55: 136-140 all three initial hepatitis B vaccines but not in the group of 10. Bommer J, Grussendorf M, Jilg W et al. Vaccination against non-responders in which the interferon-a was added only to hepatitis B in patients with renal insufficiency. Proc Eur Dial the fifth vaccine injection [15] . In the controlled, randomized Transplant Assoc Eur Ren Assoc 1985; 21: 300-305 trials performed among healthy adult non-responders by 11 Clin Microbiol 1984; 3: 195-198 higher antibody titers and earlier seroconversion among healthy adult non-responders receiving one additional doses of interferon-a [14] .
Target haematocrit during erythropoietin treatment in
In conclusion, intradermal vaccination with HBV vaccine dialysis patients. Which value is 'true-functional at short intervals is an effective method of increasing the haematocrit'? response to vaccine in chronic haemodialysis patients. This study does not support the value of concomitant interferona therapy in the augmentation of the antibody response rate Sir, among this group of patients. In order to further evaluate Correction of anaemia in dialysis patients by recombinant the response to concomitant interferon-a administration erythropoietin is an established treatment. This results in larger controlled studies with different doses and dosing better life quality, brain function, working capacity, physical frequency are required.
activity We concluded that post-dialysis Ht level is significantly elevated and remains so up to 24 h before the next dialysis Sir, session. This finding may be an important factor in the We were interested to read the clinical report by Yildiz et al. definition of the target Ht. Therefore, pre-dialysis normaliza-[1] and their experiences with tuberculosis following renal tion and over-corrected post-dialysis Ht cannot be an accept-transplantation. Twenty-two cases of tuberculosis were idenable target as it can accentuate side effects occurring during tified from 520 transplant recipients. The majority of diathe treatment of renal anaemia by recombinant gnoses were made either on the grounds of clinical features erythropoietin.
with subsequent response to anti-tuberculosis therapy or on typical histology. Dial Transplant 1997; 12: 1813 -1816 This series highlights the diagnostic difficulties associated medication. These problems stem from a number of factors.
3. Collins AJ, William KF. Higher haematocrit levels: do they Tuberculosis may present atypically, particularly in the setimprove patient outcomes, and are they cost effective ? Nephrol Dial Transplant 1998; 13: 1627 -1629 ting of immunosuppression, making a clinical diagnosis 4. Paganini EP. In search of an optimal haematocrit level in dialysis difficult. Patients may be infected with an atypical mycobacpatients: rehabilitation and quality-of-life implications. Am terium rather than M. tuberculosis or have isolates which
